145 related articles for article (PubMed ID: 26810527)
1. Clusterin CSF levels in differential diagnosis of neurodegenerative disorders.
Přikrylová Vranová H; Hényková E; Mareš J; Kaiserová M; Menšíková K; Vaštík M; Hluštík P; Zapletalová J; Strnad M; Stejskal D; Kaňovský P
J Neurol Sci; 2016 Feb; 361():117-21. PubMed ID: 26810527
[TBL] [Abstract][Full Text] [Related]
2. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
Vranová HP; Hényková E; Kaiserová M; Menšíková K; Vaštík M; Mareš J; Hluštík P; Zapletalová J; Strnad M; Stejskal D; Kaňovský P
J Neurol Sci; 2014 Aug; 343(1-2):120-4. PubMed ID: 24928081
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
Katayama T; Sawada J; Takahashi K; Yahara O; Hasebe N
Alzheimers Res Ther; 2021 Oct; 13(1):163. PubMed ID: 34610837
[TBL] [Abstract][Full Text] [Related]
6. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
[TBL] [Abstract][Full Text] [Related]
7. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
[TBL] [Abstract][Full Text] [Related]
8. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
[TBL] [Abstract][Full Text] [Related]
9. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
10. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
[TBL] [Abstract][Full Text] [Related]
11. Increased albumin CSF/serum ratio in dementia with Lewy bodies.
Llorens F; Schmitz M; Gloeckner SF; Kaerst L; Hermann P; Schmidt C; Varges D; Zerr I
J Neurol Sci; 2015 Nov; 358(1-2):398-403. PubMed ID: 26476775
[TBL] [Abstract][Full Text] [Related]
12. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R
J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease.
van Dijk KD; Jongbloed W; Heijst JA; Teunissen CE; Groenewegen HJ; Berendse HW; van de Berg WD; Veerhuis R
Parkinsonism Relat Disord; 2013 Dec; 19(12):1079-83. PubMed ID: 23932065
[TBL] [Abstract][Full Text] [Related]
15. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease.
Mollenhauer B; Bibl M; Trenkwalder C; Stiens G; Cepek L; Steinacker P; Ciesielczyk B; Neubert K; Wiltfang J; Kretzschmar HA; Poser S; Otto M
J Neural Transm (Vienna); 2005 Jul; 112(7):933-48. PubMed ID: 15937638
[TBL] [Abstract][Full Text] [Related]
16. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies.
Tam CW; Burton EJ; McKeith IG; Burn DJ; O'Brien JT
Neurology; 2005 Mar; 64(5):861-5. PubMed ID: 15753423
[TBL] [Abstract][Full Text] [Related]
17. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.
Heywood WE; Galimberti D; Bliss E; Sirka E; Paterson RW; Magdalinou NK; Carecchio M; Reid E; Heslegrave A; Fenoglio C; Scarpini E; Schott JM; Fox NC; Hardy J; Bhatia K; Heales S; Sebire NJ; Zetterberg H; Mills K
Mol Neurodegener; 2015 Dec; 10():64. PubMed ID: 26627638
[TBL] [Abstract][Full Text] [Related]
19. Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases.
Nutu M; Bourgeois P; Zetterberg H; Portelius E; Andreasson U; Parent S; Lipari F; Hall S; Constantinescu R; Hansson O; Blennow K
Neuromolecular Med; 2013 Mar; 15(1):169-79. PubMed ID: 23225274
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
